Table 1: Overall population characteristics of patients with Type 2 Diabetes Mellitus (n=52).

Age (years)62 ± 12

Female35 (66. 7%)

BMI (kg/m2)31.2 ± 5.6

Waist (cm)104 ± 22

Current smoking13 (25%)

Stroke/TIA2 (3. 8%)

CAD10 (19 2%)

Arterial Hypertension35 (67. 3%)

MAP (mmHg)96 ± 10

Duration of diabetes (months)90 (36-240)

Creatinine (mg/dl)0.8 ± 0.1

MDRD74 (67-105)

LDL (mg/dl)112 (77-123)

HDL (mg/dl)47 ± 14

Triglycerides (mg/dl)135 (96-228)

HbA1c (%)7.1 ± 1.1

TNFa (pg/ml)8.1 ± 2.4

S100-B (pg/ml)2.2 (1.9-12.3)

Medication

Insulin10 (19. 2%)

Metformin36 (69. 2%)

DPP4 inhibitors12 (23. 1%)

Sulphonylureas14 (26. 9%)

ACE/ARBs27 (51. 9%)

b-blockers18 (34. 6%)

Antiplatelet treatment17 (32. 7%)

Statin treatment28 (53. 8%)

Depressive symptoms22 (42. 3%)

Hamilton (interview) rating scale score (17)5 (3-9)

Zung self-assessment score44 ± 10

BMI: body mass index, TIA: transient ischemic attack, CAD: cardiovascular disease, MAP: mean arterial pressure (MAP = [(2 x diastolic)+systolic]/3, MDRD: GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) (mL/min/1.73 m2), LDL: low density lipoprotein, HDL: high density lipoprotein, HbA1c: glycated hemoglobin; TNFa: tumor necrosis factor a, S100B: S100 calcium binding peptide b; DPP4 inhibitors: dipeptidyl-peptidase 4 inhibitors; ACE: angiotensin-converting-enzyme inhibitor, and ARBs: angiotensin receptor blockers.